As Biohaven CEO Coric preps FDA filing for new migraine spray, he's already scouting for celebrity spokesperson
Days after reporting positive Phase III results for intranasal migraine med zavegepant, Biohaven chairman and CEO Vlad Coric is talking about marketing plans. It’s a month or more before Biohaven will file for FDA approval and likely a year before launch, but Coric is already thinking about messaging and commercialization.
His plan? A dual strategy to attract potential patients around speed to relief – zavegepant study results show the spray can provide relief in as fast as 15 minutes and a return to normal in 30 minutes – along with a secondary anti-nausea benefit in using an intranasal versus a pill.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
